FRONTIER BIOTECHNOLOGIES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.6 CNY | +1.07% |
|
-4.90% | -33.47% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 6,925 | 6,688 | 6,465 | 3,716 |
| Enterprise Value (EV) 1 | 5,183 | 5,501 | 5,503 | 3,154 |
| P/E ratio | -24.1 x | -25.8 x | -17.6 x | -11.3 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 149 x | 165 x | 76.3 x | 32.5 x |
| EV / Revenue | 111 x | 136 x | 64.9 x | 27.6 x |
| EV / EBITDA | -24.9 x | -18.2 x | -14.8 x | -9.84 x |
| EV / FCF | -18.7 x | -11.4 x | -13.6 x | -9.18 x |
| FCF Yield | -5.35% | -8.77% | -7.34% | -10.9% |
| Price to Book | 3.23 x | 3.65 x | 3.87 x | 2.77 x |
| Nbr of stocks (in thousands) | 359,760 | 359,760 | 374,579 | 374,579 |
| Reference price 2 | 19.25 | 18.59 | 17.26 | 9.920 |
| Announcement Date | 3/30/21 | 4/29/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.911 | 20.86 | 46.62 | 40.5 | 84.74 | 114.2 |
| EBITDA 1 | -237.5 | -171.7 | -208.1 | -302.7 | -371.6 | -320.6 |
| EBIT 1 | -261.5 | -209.8 | -245.6 | -321.3 | -398.6 | -344.2 |
| Operating Margin | -13,686.1% | -1,005.57% | -526.89% | -793.34% | -470.32% | -301.28% |
| Earnings before Tax (EBT) 1 | -247.2 | -195.1 | -235.5 | -265.3 | -356.8 | -329 |
| Net income 1 | -247.1 | -192.4 | -230.7 | -260.1 | -356.8 | -329 |
| Net margin | -12,928.22% | -922.58% | -494.89% | -642.07% | -421.01% | -287.93% |
| EPS 2 | -1.023 | -0.7266 | -0.8000 | -0.7200 | -0.9800 | -0.8800 |
| Free Cash Flow 1 | -40.59 | -205 | -277.1 | -482.6 | -403.7 | -343.6 |
| FCF margin | -2,124.17% | -982.79% | -594.26% | -1,191.59% | -476.36% | -300.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/13/20 | 8/13/20 | 3/30/21 | 4/29/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Net sales | 5.858 | 5.67 | 20.5 | 31.49 | 27.08 | - |
| EBITDA | -43.14 | - | -71.4 | -111.1 | - | - |
| EBIT | -105.4 | -134 | -63.58 | -105 | -129.7 | - |
| Operating Margin | -1,799.59% | -2,363.99% | -310.21% | -333.51% | -479.09% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | - | - | - | - | - | -75.71 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.2300 | -0.1600 | -0.1800 | -0.2900 | -0.3500 | -0.2000 |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 2/25/22 | 4/29/22 | 8/30/22 | 10/25/22 | 2/27/23 | 4/28/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 363 | 372 | 1,743 | 1,187 | 962 | 561 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -40.6 | -205 | -277 | -483 | -404 | -344 |
| ROE (net income / shareholders' equity) | -43.3% | -31.4% | -17.2% | -13.4% | -20.4% | -21.8% |
| ROA (Net income/ Total Assets) | -25.3% | -15.8% | -8.89% | -7.96% | -10.1% | -9.45% |
| Assets 1 | 974.7 | 1,221 | 2,597 | 3,269 | 3,540 | 3,479 |
| Book Value Per Share 2 | 2.630 | 2.230 | 5.960 | 5.090 | 4.460 | 3.580 |
| Cash Flow per Share 2 | 0.7700 | 0.8400 | 2.330 | 2.230 | 1.470 | 1.410 |
| Capex 1 | 37.5 | 160 | 186 | 327 | 140 | 129 |
| Capex / Sales | 1,959.9% | 769.41% | 399.83% | 807.72% | 165.65% | 113.22% |
| Announcement Date | 8/13/20 | 8/13/20 | 3/30/21 | 4/29/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -33.47% | 339M | |
| +10.23% | 9.11B | |
| -10.76% | 5.21B | |
| +51.58% | 4.83B | |
| +12.50% | 4.09B | |
| -20.70% | 2.35B | |
| +12.83% | 2.32B | |
| +19.51% | 2.27B | |
| -29.65% | 2.19B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 688221 Stock
- Financials Frontier Biotechnologies Inc.
